News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Natera Acquires Foresight Diagnostics

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

Natera (NASDAQ:NTRA) was given a new $265.00 price target on by analysts at Morgan Stanley.

Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an "overweight" rating on the stock.

11/6/2025

04:05 pm

ntra

0.5%

MISS

8/7/2025

04:05 pm

ntra

7.7%

MISS

5/8/2025

04:05 pm

ntra

-7.3%

BEAT

2/27/2025

04:05 pm

ntra

-3.7%

BEAT

Form S-8 Natera, Inc.

Form S-3 Natera, Inc.

Form 8-K Natera, Inc. For: Dec 04

Form 4 Natera, Inc. For: Dec 01 Filed by: Chapman Steven Leonard

Form 4 Natera, Inc. For: Dec 01 Filed by: Moshkevich Solomon

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}